Literature DB >> 8599866

In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes.

A Mori1, S P Wu, I Han, A R Khokhar, R Perez-Soler, L Huang.   

Abstract

A lipophilic cisplatin derivative, cis-bis-neodecanoato-trans- R,R-1,2-diaminocyclohexane platinum (II) (NDDP), was formulated in liposomes composed of phosphatidylcholine (PC) and cholesterol (Chol) additionally containing monosialoganglioside (Gm1) or polyethyleneglycol conjugated to phosphatidylethanolamine (PEG-PE). These NDDP-containing long-circulating liposomes were examined for in vivo antitumor activity using the mouse RIF-1 solid tumor as a target residing outside the reticuloendothelial system (RES). Biodistribution studies, using C3H/HeJ mice and 111In-labelled DTPA-SA as a lipid marker, showed that the activity of GM1 and PEG-PE in prolonging the circulation times of liposomes was preserved in the presence of 3.0 mol% of NDDP in the liposome membranes. The high levels of liposomes remaining in the blood for PC/Chol/GM1 and PC/Chol/PEG3000-PE liposomes were associated with high levels of platinum in the blood as determined by atomic absorption spectrophotometry. These NDDP-containing long-circulating liposomes showed approximately a three-fold increase in tumor accumulation as compared to the conventional PC/Chol liposomes. In vitro cytotoxicity studies using RIF-1 tumor cells showed that the presence of PEG-PE, but not Gm1, significantly enhanced the cytotoxicity of liposomal NDDP. RIF-1 tumor-bearing C3H/HeJ mice were treated twice with 25 mg/kp NDDP in various liposomal formulations on days 12 and 16 after tumor cell inoculation. A significant reduction in the tumor growth rate was observed when NDDP was formulated in PC/Chol/PEG3000-PE liposomes which support both efficient tumor accumulation and enhanced cytotoxicity of liposomal NDDP. On the other hand, NDDP formulated in PC/Chol/GM1 liposomes, which display only a high tumor accumulation, had no effect on the tumor growth rate. Furthermore, NDDP formulated in dimyristoylphosphatidylglycerol (DMPG)-containing liposomes, exhibiting in vitro cytotoxicity comparable to NDDP formulated in PC/Chol/PEG3000-PE liposomes, but showing poor tumor accumulation, was also not effective. These results indicate a potential effectiveness of NDDP formulated in PEG-PE-containing liposomes for therapy of tumors in non-RES organs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599866     DOI: 10.1007/s002800050409

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  46 in total

1.  Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes.

Authors:  D Liu; A Mori; L Huang
Journal:  Biochim Biophys Acta       Date:  1992-02-17

2.  Small-volume extrusion apparatus for preparation of large, unilamellar vesicles.

Authors:  R C MacDonald; R I MacDonald; B P Menco; K Takeshita; N K Subbarao; L R Hu
Journal:  Biochim Biophys Acta       Date:  1991-01-30

Review 3.  The separation of cells and organelles by partitioning in two-polymer aqueous phases.

Authors:  D Fisher
Journal:  Biochem J       Date:  1981-04-15       Impact factor: 3.857

4.  Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo.

Authors:  A Mori; A L Klibanov; V P Torchilin; L Huang
Journal:  FEBS Lett       Date:  1991-06-24       Impact factor: 4.124

5.  Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies.

Authors:  A Gabizon; D C Price; J Huberty; R S Bresalier; D Papahadjopoulos
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

6.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

Authors:  A Gabizon; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

7.  Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity.

Authors:  R Perez-Soler; A R Khokhar
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

8.  Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes.

Authors:  D C Litzinger; A M Buiting; N van Rooijen; L Huang
Journal:  Biochim Biophys Acta       Date:  1994-02-23

9.  Enhanced tumor targeting of doxorubicin by ganglioside GM1-bearing long-circulating liposomes.

Authors:  S Unezaki; K Maruyama; O Ishida; N Takahashi; M Iwatsuru
Journal:  J Drug Target       Date:  1993       Impact factor: 5.121

10.  Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles.

Authors:  R Perez-Soler; L Y Yang; B Drewinko; J Lauterzstain; A R Khokhar
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

View more
  3 in total

1.  Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.

Authors:  Heidi M Kieler-Ferguson; Darren Chan; Jonathan Sockolosky; Lydia Finney; Evan Maxey; Stefan Vogt; Francis C Szoka
Journal:  Eur J Pharm Sci       Date:  2017-03-03       Impact factor: 4.384

2.  Circumventing tumor resistance to chemotherapy by nanotechnology.

Authors:  Xing-Jie Liang; Chunying Chen; Yuliang Zhao; Paul C Wang
Journal:  Methods Mol Biol       Date:  2010

Review 3.  Application of liposomal technologies for delivery of platinum analogs in oncology.

Authors:  Demin Liu; Chunbai He; Andrew Z Wang; Wenbin Lin
Journal:  Int J Nanomedicine       Date:  2013-08-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.